Date: 2016-02-22
Type of information: Collaboration agreement
Compound:
Company: Aptuit (UK) Icagen (USA - NC)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On February 22nd, 2016, Aptuit and Icagen announced a strategic alliance to give drug discovery customers access to ion channel and transporter technologies and expert services. Aptuit is a global drug discovery and development CRO. Icagen is a CRO with scientific expertise and comprehensive access to technologies for ion channel and transporter assays. The partners will offer comprehensive and integrated services from gene to high quality candidates and beyond in the ion channel and transporter area. This partnership is expected to allow the two companies to jointly offer best-in-class fully integrated drug discovery and development solutions for the specific target classes, supported by a shared culture of scientific excellence and innovation. The strategic alliance will give Aptuit’s customers access to Icagen's portfolio of assay tools and technologies for ion channel and transporter research, including their extensive collection of unique ion channel cell lines and their proprietary XRpro® X-ray fluorescence technology platform. Icagen's customers are expected to benefit from Aptuit's wide range of integrated drug discovery solutions, including medicinal chemistry, in vitro DMPK, discovery pharmacology, computational chemistry and best-in-class analytical discovery support.
Financial terms:
Latest news:
